1. Hall GW: Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001;112(4):851-862.
2. Kwok-Williams M, Perez Z, Squire R, Glaser A, Bew S, Taylor R. Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome. _2007;49(5):739-44.
3. Chung T, Hoffer FA, Burrows PE, et al. MR imaging ofhepatic hemangiomas ofinfancy and changes seen with interferon alpha-2a treatment. Pediatr Radiol 1996;26(5):341-348.
4. Akyuz C, Yaris N, Kutluk MT, et al. Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol 2001;18(1): 47-55.
5. Koerper MA, Addiego JE Jr, deLorimier AA, et al. Use ofaspirin and dipyridamole in children with platelet trapping syndromes. J Pediatr 1983;102(2):311-314.
6. Prost Y, Teillac D, Bodemer C, et al. Successful treatment of Kasabach -Merritt syndrome with pentoxifylline. J Am Acad Dermatol 1991;25(5 Pt
1):854-855.
7. Dresse MF, David M, Hume H, et al. Successful treatment of Kasabach -Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 1991;8(4):329-334.
8. Ezekowitz A, Mulliken J, Folkman J. Interferon alpha therapy ofhaemangiomas in newborns and infants. Br JHaematol 1991;79(Suppl 1):67-68.
9. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326(22):1456-1463.
10. Harper L, Michel JL, Enjolras O, Raynaud-MounetN, Riviere JP, Heigele T, De Napoli-Cocci S. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon. Eur J Pediatr Surg. 2006;16(5):369-72.
S.D.Ü. Tıp pak.
Derg
. 2012:19(2)/55-58
58
Canatan, vincristine and Kasabach-Merritt Phenomenon
11. Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, de Laat PC, Madern GC, Gonzalez F, Frangoul H, Le Moine P, Prose NS, Adams DM. Kasabach-Merritt phenomenon: a retrospective study oftreatment with vincristine. J Pediatr Hematol Oncol
2002;24(6):459-462.
12. Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review ofliterature. Cases J 2008;1(1):9.
13. Yesudian PD, Parslew R, Klafowski J, Gould D, Pizer B. Tufted angioma-associated Kasabach-Merritt syndrome treated with embolization and vincristine. Plast Reconstr Surg. 2008;121(2):692-3.
14. Thomson K, Pinnock R, Teague L, Johnson R, Manikkam N, Drake R. Vincristine for the treatment ofKasabach-Merritt syndrome: recentNew Zealand case experience. N Z Med J. 2007;120(1249):U2418.
15. Taki M, Ohi C, Yamashita A, Kobayashi M, Kobayashi N, Yoda T, Horiuchi T, Aikyou M, Horikoshi Y, Mimaya J. Successful treatment with vincristine ofan infant with intractable Kasabach-Merritt syndrome. PediatrInt. 2006;48(1):82-4.
16. Hoyoux C: Vincristine treatment for management of alarming hemangiomas in infancy. Rev Med Liege.2008;63(1):14-7.
Thank you for copying data from http://www.arastirmax.com